184 related articles for article (PubMed ID: 27233518)
1. Rat Osteosarcoma Cells as a Therapeutic Target Model for Osteoregeneration via Sclerostin Knockdown.
Sedaghati B; Jahroomishirazi R; Starke A; Hacker MC; Schulz-Siegmund M
Cells Tissues Organs; 2016; 201(5):366-79. PubMed ID: 27233518
[TBL] [Abstract][Full Text] [Related]
2. Effects of SOST Gene Silencing on Proliferation, Apoptosis, Invasion, and Migration of Human Osteosarcoma Cells Through the Wnt/β-Catenin Signaling Pathway.
Zou J; Zhang W; Li XL
Calcif Tissue Int; 2017 Jun; 100(6):551-564. PubMed ID: 28246931
[TBL] [Abstract][Full Text] [Related]
3. Sclerostin expression is induced by BMPs in human Saos-2 osteosarcoma cells but not via direct effects on the sclerostin gene promoter or ECR5 element.
Yu L; van der Valk M; Cao J; Han CY; Juan T; Bass MB; Deshpande C; Damore MA; Stanton R; Babij P
Bone; 2011 Dec; 49(6):1131-40. PubMed ID: 21890009
[TBL] [Abstract][Full Text] [Related]
4. Spaciotemporal association and bone morphogenetic protein regulation of sclerostin and osterix expression during embryonic osteogenesis.
Ohyama Y; Nifuji A; Maeda Y; Amagasa T; Noda M
Endocrinology; 2004 Oct; 145(10):4685-92. PubMed ID: 15217980
[TBL] [Abstract][Full Text] [Related]
5. Sclerostin expression in skeletal sarcomas.
Shen J; Meyers CA; Shrestha S; Singh A; LaChaud G; Nguyen V; Asatrian G; Federman N; Bernthal N; Eilber FC; Dry SM; Ting K; Soo C; James AW
Hum Pathol; 2016 Dec; 58():24-34. PubMed ID: 27498059
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of GSK3β Stimulates BMP Signaling and Decreases SOST Expression Which Results in Enhanced Osteoblast Differentiation.
Schoeman MA; Moester MJ; Oostlander AE; Kaijzel EL; Valstar ER; Nelissen RG; Löwik CW; de Rooij KE
J Cell Biochem; 2015 Dec; 116(12):2938-46. PubMed ID: 26095393
[TBL] [Abstract][Full Text] [Related]
7. SOST is a target gene for PTH in bone.
Keller H; Kneissel M
Bone; 2005 Aug; 37(2):148-58. PubMed ID: 15946907
[TBL] [Abstract][Full Text] [Related]
8. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone.
Silvestrini G; Ballanti P; Leopizzi M; Sebastiani M; Berni S; Di Vito M; Bonucci E
J Mol Histol; 2007 Aug; 38(4):261-9. PubMed ID: 17549589
[TBL] [Abstract][Full Text] [Related]
9. Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells.
Papanicolaou SE; Phipps RJ; Fyhrie DP; Genetos DC
Biorheology; 2009; 46(5):389-99. PubMed ID: 19940355
[TBL] [Abstract][Full Text] [Related]
10. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation.
Sutherland MK; Geoghegan JC; Yu C; Turcott E; Skonier JE; Winkler DG; Latham JA
Bone; 2004 Oct; 35(4):828-35. PubMed ID: 15454089
[TBL] [Abstract][Full Text] [Related]
11. Control of the SOST bone enhancer by PTH using MEF2 transcription factors.
Leupin O; Kramer I; Collette NM; Loots GG; Natt F; Kneissel M; Keller H
J Bone Miner Res; 2007 Dec; 22(12):1957-67. PubMed ID: 17696759
[TBL] [Abstract][Full Text] [Related]
12. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis.
Bellido T; Ali AA; Gubrij I; Plotkin LI; Fu Q; O'Brien CA; Manolagas SC; Jilka RL
Endocrinology; 2005 Nov; 146(11):4577-83. PubMed ID: 16081646
[TBL] [Abstract][Full Text] [Related]
13. Localization of SOST/sclerostin in cementocytes in vivo and in mineralizing periodontal ligament cells in vitro.
Jäger A; Götz W; Lossdörfer S; Rath-Deschner B
J Periodontal Res; 2010 Apr; 45(2):246-54. PubMed ID: 19778325
[TBL] [Abstract][Full Text] [Related]
14. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist.
van Bezooijen RL; Roelen BA; Visser A; van der Wee-Pals L; de Wilt E; Karperien M; Hamersma H; Papapoulos SE; ten Dijke P; Löwik CW
J Exp Med; 2004 Mar; 199(6):805-14. PubMed ID: 15024046
[TBL] [Abstract][Full Text] [Related]
15. Methylation of bone SOST, its mRNA, and serum sclerostin levels correlate strongly with fracture risk in postmenopausal women.
Reppe S; Noer A; Grimholt RM; Halldórsson BV; Medina-Gomez C; Gautvik VT; Olstad OK; Berg JP; Datta H; Estrada K; Hofman A; Uitterlinden AG; Rivadeneira F; Lyle R; Collas P; Gautvik KM
J Bone Miner Res; 2015 Feb; 30(2):249-56. PubMed ID: 25155887
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation contributes to the regulation of sclerostin expression in human osteocytes.
Delgado-Calle J; Sañudo C; Bolado A; Fernández AF; Arozamena J; Pascual-Carra MA; Rodriguez-Rey JC; Fraga MF; Bonewald L; Riancho JA
J Bone Miner Res; 2012 Apr; 27(4):926-37. PubMed ID: 22162201
[TBL] [Abstract][Full Text] [Related]
17. The effect of TNFα secreted from macrophages activated by titanium particles on osteogenic activity regulated by WNT/BMP signaling in osteoprogenitor cells.
Lee SS; Sharma AR; Choi BS; Jung JS; Chang JD; Park S; Salvati EA; Purdue EP; Song DK; Nam JS
Biomaterials; 2012 Jun; 33(17):4251-63. PubMed ID: 22436801
[TBL] [Abstract][Full Text] [Related]
18. 1α,25-dihydroxyvitamin D3 stimulates human SOST gene expression and sclerostin secretion.
Wijenayaka AR; Yang D; Prideaux M; Ito N; Kogawa M; Anderson PH; Morris HA; Solomon LB; Loots GG; Findlay DM; Atkins GJ
Mol Cell Endocrinol; 2015 Sep; 413():157-67. PubMed ID: 26112182
[TBL] [Abstract][Full Text] [Related]
19. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.
Kim JY; Lee SK; Jo KJ; Song DY; Lim DM; Park KY; Bonewald LF; Kim BJ
Life Sci; 2013 Mar; 92(10):533-40. PubMed ID: 23357248
[TBL] [Abstract][Full Text] [Related]
20. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism.
Atkins GJ; Rowe PS; Lim HP; Welldon KJ; Ormsby R; Wijenayaka AR; Zelenchuk L; Evdokiou A; Findlay DM
J Bone Miner Res; 2011 Jul; 26(7):1425-36. PubMed ID: 21312267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
